Fujifilm Medical Systems debuted at RSNA 20009 the Aspire HD* FFDM system for the first time in the U.S. The Aspire HD combines the use of advanced dual-layer amorphous selenium (a-Se) next generation detector technology and a small pixel size to deliver lower noise and higher spatial resolution at a reduced dose for the patient. The flexible Aspire HD system is poised to deliver next generation imaging performance and a platform for advanced three dimensional (3D) applications.
Coupled with a recent strategic licensing agreement with Raytheon BBN Technologies, an advanced technology solutions firm in Cambridge, Mass., who will provide Fujifilm with its patented Stereo Digital Mammography (SDM) technology, the detector development will not only offer 2D full-field digital mammography (FFDM) images but serve as the foundation for future 3D applications.
Already used in countries throughout the world as AMULET, the Aspire HD is a FFDM system that uses dual layers of amorphous selenium (a-Se) in its detector. Combined with direct optical switching (DOS) and legacy 50-micron resolution, the system delivers image quality.
The DOS technology eliminates the use of Thin Film Transistors (TFTs), which are currently used in other FFDM systems. By eliminating the TFTs, this new technology enables the 50-micron resolution and high efficiency image capture. The result is that the Aspire HD is said to produce images with less noise and reduced dose, while delivering the performance and reliability digital mammography users have come to expect from Fujifilm. Other benefits of the system include its unique ergonomic design for comfort and to enable maximum access to the chest wall.
* The Aspire HD is known as the AMULET outside the U.S. The Aspire HD requires FDA approval and are not yet available for sale in the U.S.
July 29, 2024 
